EN-见闻·Voice of ACRO—Nov.28（March)_副本

百普赛斯

ACRO Activity Update

Employee Story 人物记  

Staff story

ACRO Voice ACRO 声音 

Knowledge Sharing

Customer Feedback

Prize Collection

目录

AFT team organized a series of interesting New Year's events, in which many employees actively participated and received gifts.

龙/年/大/吉

HAPPY NEW YEAR

恭贺新春    万事如意

SPRING FESTIVAL

Company News

01

ACRO News 公司动态 

Marketing Activity Update

ACRO Activity Update

23rd Annual PepTalk -

The Protein Science and Production Week

ACROBiosystems Honored: "2023 Best Employer Management Practices Award"

New Year Activities

02

03

责编

New Year Activities From: AFT Tianyu Han

23rd Annual PepTalk - The Protein Science and Production Week From: MKT Ruifeng Jiang

ACROBiosystems Honored: "2023 Best Employer Management Practices Award"  From: HR Zexin Deng

Jan & Feb New Staff From： HR-Liwan Zhao

Knowledge sharing From: Trainee Yangwei

Blessing Expressions From: HR Emily Situ

Customer Feedback From：CE-Wang Xin

Editorial Committee

ACROBiosystems Honored: "2023 Best Employer Management Practices Award"

Blessing Expressions

New Year Activities

"New Year, New Beginnings: To Open a New Chapter with Acro"

Lentiviral vectors of viral vectors

百普赛斯

百普赛斯

百普赛斯

From: AFT Tianyu Han

HAPPY NEW YEAR

百普赛斯

百普赛斯

百普赛斯

百普赛斯

23rd Annual PepTalk - 

The Protein Science and Production Week

In January, our US team exhibited at PepTalk 2024 in San Diego. We had the privilege of engaging with numerous attendees, and we extended our warm congratulations to the winners who walked away with their llama prizes. Peter Hsueh, PhD., who presented an insightful poster titled 'Product and Impurity QC for Reagents Used in Biopharma Manufacturing' (Poster B02) was the highlight of the event. His valuable knowledge and insight shed light on the crucial quality control aspects of reagents utilized in biopharmaceutical manufacturing. We are proud of our team's accomplishments and the positive engagement they received at the event.

From: MKT Ruifeng Jiang

ACROBiosystems Honored: "2023 Best Employer Management Practices Award"

In December 2023, Beisen announced its annual list of Best Employers for 2023, and ACROBiosystems received the 2023 Best Employer Management Practices Award.

The award recognizes the milestones that ACROBiosystems has been achieving in its continuous efforts and innovative practices to enhance the impact of the employer brand. ACROBiosystems is dedicated to accelerating the drug development process and helping to bring them to market. Our mission is to actualize the clinical application of novel, innovative therapies and contribute to the biomedicine industry. Through our efforts, we would like to start by bringing value to our customers to creating value for the whole industry in the global market. The company continues to actively empower its partners by updating its technology, products, and services. In this way, we can accelerate the R&D and marketing process of various biopharmaceuticals, including target drugs and immunotherapeutic drugs, as well as better clinical applications, and ultimately contribute to the cause of human health.

From: HR Zexin Deng

Marketing Activity Update

Employee Story

Staff story

"New Year, New Beginnings: 

To Open a New Chapter with Acro"

Celebrating the first New Year at ACRO has been a special and memorable experience in my professional journey. This moment not only allows me to reflect on past achievements but also fills me with anticipation for the future. Here are my reflections and aspirations for the first New Year spent at ACRO:

From: HR Leihao

百普赛斯

百普赛斯

The New Year is an ideal moment to review the past year at ACRO. Over this time, I faced numerous challenges and opportunities, continually learning and growing. From being a newcomer to a valued team member, I could sense my progress and integration within the team. Collaborating with colleagues, we completed various projects, contributing to the company's development.

The New Year signifies new beginnings and possibilities. At ACRO, I realize that each day presents a fresh opportunity for innovation and progress. I encourage myself to remain curious, bravely try new methods and perspectives, and bring creativity and vitality to the team.

New Year, New Perspectives

Looking Ahead

In the new year, I carry with me more aspirations and expectations. I will continue to strive for learning, enhancing my professional skills, and contributing more to the company's development. Simultaneously, I look forward to embracing new challenges with the team and creating more success stories together. At ACRO, I believe each new year will mark a new chapter of collective efforts and achievements.

In summary, ACRO has provided a dynamic and opportunistic work environment. The first New Year spent here has been enriching, instilling confidence in the future. I look forward to growing with ACRO, jointly embarking on new journeys, and creating a brighter tomorrow.

Shared Moments with the Team

New Year is a time for togetherness, and I am grateful to share this special time with ACRO's team. In this big family, we share joys and achievements, collectively facing the challenges of the upcoming year. The team's cohesion brings warmth and inspiration, reinforcing my belief that, together, we can create a more brilliant future.

百普赛斯

百普赛斯

ACRO Voice

Introduction

At present, viral vectors are mainly developed from four types of viruses: adenovirus, adeno-associated virus (AAV), lentivirus, and retrovirus. Adenoviruses and AAV efficiently infect host cells in free form and express large amounts of the proteins encoded by the foreign genes they carry. In contrast, retroviruses and lentiviruses integrate into the host cell genome. These vectors do not kill host cells and can be used to stably transfect mammalian cells. No single cell line can be infected by all viral vectors, and retroviruses have strong species specificity and a clear preference for dividing cells.

Lentivirus vector (LV) is a kind of vector derived from retrovirus. The reason why lentivirus is called lentivirus is that the main clinical characteristics of infection are a long incubation period before the appearance of typical clinical symptoms and then slow onset. The most classical lentivirus is modified from HIV, and the HIV-1/HIV-2 system has also been widely used. Subsequently, there are simian immunodeficiency virus (SIV) vector systems, felines immunodeficiency virus (FIV) vector systems, and so on.

Lentivirus is a gene therapy vector based on HV-1. The first-generation two-plasmid system lentiviral vector encodes all packaging elements in a single vector with high biosafety risk. The second generation of three-plasmid lentiviral vectors deleted all HIV accessory genes vif, vpu, vpr and nef to reduce the risk of RCR production. Replication of the promoter activity did not affect virion titer. The 3’LTR of the U3 region was deleted in the third generation of the four-plasmid system lentivirus vector so that the vector lost the HIV-1 enhancer and promoter sequence and could not transcribe RNA even in the presence of all viral proteins. At the same time, the tat gene was removed and replaced by a heterologous promoter sequence. The third generation is the currently popular lentiviral packaging vector.

Knowledge sharing

Lentiviral vectors of viral vectors

Figure 1: Lentiviral vectors of the third-generation four-plasmid system.

√Once a lentiviral vector infects a cell, the RNA genome of the virus is reverse transcribed into DNA, which is then permanently integrated into the host genome, thereby allowing long-term stable expression of the genes carried on the viral vector. That is to construct stable cell lines.

√Lentiviral vectors are capable of infecting both dividing and non-dividing cells.

√Lentiviral vectors could infect many types of cells, such as neuronal cells, hepatocytes, cardiomyocytes, tumor cells, endothelial cells, and stem cells.

To package a complete lentivirus, we generally need the following plasmids:

① A shuttle plasmid: this is the "protagonist" carrying our target gene in the LTR region of both ends, but it is replication-defective, so it is not enough alone, and the assistance of the following plasmid is needed.

② One or two packaging plasmids

③ An envelope plasmid

Then these plasmids were co-transferred into 293T cells, and the packaged virus would be released into the supernatant. The viral supernatant was collected and concentrated (or you cannot concentrate, directly use the supernatant), and then we could infect our target cells.

慢病毒载体感染细胞

包装完成得到的慢病毒就可以用来感染细胞啦。首先慢病毒通过膜融合或内吞的方式进入细胞释放RNA，在逆转录酶、整合酶等的作用形成DNA整合前复合体进入细胞核并随机整合到宿主细胞的基因组中，随后开始转录翻译，这样就完成了细胞感染的过程。

 accessory genes vif, vpu, vpr and nef to reduce the risk of RCR production. Replication of the promoter activity did not affect virion titer. The 3’LTR of the U3 region was deleted in the third generation of the four-plasmid system lentivirus vector so that the vector lost the HIV-1 enhancer and promoter sequence and could not transcribe RNA even in the presence of all viral proteins. At the same time, the tat gene was removed and replaced by a heterologous promoter sequence. The third generation is the currently popular lentiviral packaging vector.

知识分享——传统吉祥话英文表达

百普赛斯

百普赛斯

来源：HR-邓泽昕

Figure 2: Flow of lentivirus-infected cells

√Protein expression, stable strain construction. With the help of the ability of lentivirus to integrate sequences into the host genome to complete stable gene expression.

√CAR-T, CAR-NK, and other cell therapy. The use of viral vectors to transfer specific CAR genes to T cells or NK cells, lentiviral vectors are the current popular choice.

√Lentivirus vector-mediated RNAi technology. LV-RNAi mediates RNAi transfection efficiency and expands the range of vector-infected cells, which can be used to study cell-specific gene function and gene therapy.

√Gene editing. Genetic modification including gene therapy, CRISPR, etc., can involve lentiviral vectors.

√For the construction of pseudo viruses. It is applied to the detection of serum-neutralizing antibodies and lays the foundation for the subsequent screening and evaluation of monoclonal antibodies and antiviral drugs, vaccine development, and virus infection mechanism research.

√Well, having said so much, I believe you have a certain understanding of lentiviral vectors. We look forward to more and more lentivirus vector-related products being launched in the future and further expanding our market share. Let's fight together!

From: Trainee Yangwei

After packaging, the lentivirus can be used to infect cells. First, lentivirus enters cells through membrane fusion or endocytosis to release RNA. Then, through the action of reverse transcriptase and integrase, lentivirus forms a DNA reintegration complex to enter the nucleus and randomly integrate into the genome of the host cell and then starts transcription and translation.

百普赛斯

百普赛斯

百普赛斯

百普赛斯

From: HR Emily Situ

Customer Feedback

来源：HR-邓泽昕

Zufriedenstellende Produktlieferung, manchmal etwas verzögert, jedoch sehr zuvorkommend

我们在Acro订购产品时有很好的体验。沟通快捷高效。

It would be really helpful to indicate the storage requirements on the outside of the box. We had a close call where the package was almost left out overnight simply because we didnt know exactly what was inside and HOW it needed to be stored upon receipt. I highly encourage you to consider this. If we are going to keep ordering from you all, this is definitely something we would expect moving forward especially because most vendor we deal with, do this.

Do you have any suggestions and feedback？

We really like to products from Aero, they deliver timely and good quality.

Very quick to respond to a request for a quote or questions. But a bit overwhelming when they insist multiple time to ask about the becoming of the quote. Tho still very friendly.

The most recent order was from a new client who could not find his antigen at a reasonable price through other vendors. I have purchased reagents from ACRO during the past 8 years and the products are always very high quality.

We look forward to future business with you!

From: CE Wang Xin

Thank you very much for your great help. It is a strong trust in Acro for our customers and us.

百普赛斯

百普赛斯

Jan & Feb New Employees

Wang  Yanyan

ARD

R&D Engineer

Jia  Ruiyu

bioSeedin

Pharmaceutical Project Analyst Intern

Wang  Shanshan

BS

Pathology Validation Senior Engineer

Xia  Yu

DSP

Protein Purification Specialist

Anil Kumar

EUR

Senior Sales Account Manager

Dong  Yingjuan

MKT

Senior Digital Marketing Specialist

Zhou  Yunqing

PD

Organoid R&D Senior Engineer

Zhang  Hengyuan

QC

Quality Control Engineer

Wu  Shaoxiong

Sales

Technical Sales Specialist

Eric Bueter

US

Associate Regional Manager

Wang  Yanna

PRD

R&D Specialist

From: HR Zhao Liwan

Best Editor Awards announced:

John Miao, PAD, MKT——ACROBiosystems' Appearance on Beijing TV! Exploration and Achievement of "Integrating Two Industries"!

Hao Lei——"ACRO Company HR Internship: Three Months of Growth and Experience"

Emily Situ——ACROBiosystems Establishes Industrial Scholarship at Peking University School of Life Sciences

Newsletter content contributors:

As we continue to move forward to the year, we hope to hear more voices and receive more stories from you. We encourage employees to submit articles on the following topics. Once accepted, there will be points distributed~ Gifts are available!

Company News (new event announcements, new developments of the month, etc.)

Knowledge sharing column (trivia, book sharing, etc.)

Team stories (tackling tough projects, the happy moments of team building, etc.)

Please send your article to zexin.deng @acrobiosystems.com.

请获奖的同学来人力资源部领取礼物~

Incentive Policies：

Prize collection

New Year Activities From: AFT Tianyu Han

23rd Annual PepTalk - The Protein Science and Production Week From: MKT Ruifeng Jiang

ACROBiosystems Honored: "2023 Best Employer Management Practices Award" From: HR Zexin Deng

Jan & Feb New Staff From： HR-Liwan Zhao

Knowledge sharing From: Trainee Yangwei

Blessing Expressions From: Emily Situ

Customer Feedback From：CE-Wang Xin